Cite
Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data.
MLA
Mohammadi, M., et al. “Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data.” Targeted Oncology, 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1380688402&authtype=sso&custid=ns315887.
APA
Mohammadi, M., Ijzerman, N. S., Hollander, D. den, Bleckman, R. F., Oosten, A. W., Desar, I. M. E., Reyners, A. K., Steeghs, N., & Gelderblom, H. (2023). Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data. Targeted Oncology.
Chicago
Mohammadi, M., N.S. Ijzerman, D. den Hollander, R.F. Bleckman, A.W. Oosten, I.M.E. Desar, A.K. Reyners, N. Steeghs, and H. Gelderblom. 2023. “Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data.” Targeted Oncology. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1380688402&authtype=sso&custid=ns315887.